Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses-Reference-Cited by-同舟云学术

Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses

Published:2012-07 Issue:30 Volume:287 Page:25266-25279
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Joubert Marisa K.,Hokom Martha,Eakin Catherine,Zhou Lei,Deshpande Meghana,Baker Matthew P.,Goletz Theresa J.,Kerwin Bruce A.,Chirmule Naren,Narhi Linda O.,Jawa Vibha

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference65 articles.

1. Overlooking subvisible particles in therapeutic protein products. Gaps that may compromise product quality;Carpenter;J. Pharm. Sci.,2009

2. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development;den Engelsman;Pharm. Res.,2011

3. Effects of protein aggregates. An immunologic perspective;Rosenberg;AAPS J.,2006

4. Impact of product-related factors on immunogenicity of biotherapeutics;Singh;J. Pharm. Sci.,2011

5. Where disease pathogenesis meets protein formulation. Renal deposition of immunoglobulin aggregates;Demeule;Eur. J. Pharm. Biopharm.,2006

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Destructive Analysis of Subvisible Particles with Mie-Scattering-Based Light Sheet Technology: System Development;Journal of Pharmaceutical Sciences;2024-09

2. Submicron immunoglobulin particles exhibit FcγRII-dependent toxicity linked to autophagy in TNFα-stimulated endothelial cells;Cellular and Molecular Life Sciences;2024-08-30

3. Biosensing-based quality control monitoring of the higher-order structures of therapeutic antibody domains;Analytica Chimica Acta;2024-05

4. A Human Skin Explant Test as a Novel In Vitro Assay for the Detection of Skin Sensitization to Aggregated Monoclonal Antibodies;Toxics;2024-04-30

5. Enrichment strategy and initial characterization of heterodimers enriched from a co-formulated cocktail of therapeutic antibodies against SARS-COV-2;mAbs;2024-04-09